JP2016515141A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016515141A5 JP2016515141A5 JP2016502876A JP2016502876A JP2016515141A5 JP 2016515141 A5 JP2016515141 A5 JP 2016515141A5 JP 2016502876 A JP2016502876 A JP 2016502876A JP 2016502876 A JP2016502876 A JP 2016502876A JP 2016515141 A5 JP2016515141 A5 JP 2016515141A5
- Authority
- JP
- Japan
- Prior art keywords
- egfr
- biomarker
- treatment
- pharmaceutical composition
- absence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 64
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 64
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 64
- 239000000090 biomarker Substances 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 41
- 238000011282 treatment Methods 0.000 claims description 26
- 206010061968 Gastric neoplasm Diseases 0.000 claims description 24
- 239000012472 biological sample Substances 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 15
- 210000000582 semen Anatomy 0.000 claims description 13
- 101150039808 Egfr gene Proteins 0.000 claims description 12
- 108700021358 erbB-1 Genes Proteins 0.000 claims description 12
- 239000012530 fluid Substances 0.000 claims description 12
- 239000000523 sample Substances 0.000 claims description 11
- 230000004544 DNA amplification Effects 0.000 claims description 10
- 230000002018 overexpression Effects 0.000 claims description 10
- 238000001574 biopsy Methods 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- 206010003445 Ascites Diseases 0.000 claims description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 4
- 210000000981 epithelium Anatomy 0.000 claims description 4
- 210000004209 hair Anatomy 0.000 claims description 4
- 210000003780 hair follicle Anatomy 0.000 claims description 4
- 210000004880 lymph fluid Anatomy 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 238000012544 monitoring process Methods 0.000 claims description 4
- 210000002200 mouth mucosa Anatomy 0.000 claims description 4
- 210000004877 mucosa Anatomy 0.000 claims description 4
- 210000002307 prostate Anatomy 0.000 claims description 4
- 210000003296 saliva Anatomy 0.000 claims description 4
- 210000003491 skin Anatomy 0.000 claims description 4
- 210000004243 sweat Anatomy 0.000 claims description 4
- 210000001138 tear Anatomy 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 238000011269 treatment regimen Methods 0.000 claims description 4
- 210000002700 urine Anatomy 0.000 claims description 4
- 210000004907 gland Anatomy 0.000 claims description 3
- 239000013610 patient sample Substances 0.000 claims description 3
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 2
- 229940043275 anti-HER2 drug Drugs 0.000 claims description 2
- 229960004117 capecitabine Drugs 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 190000008236 carboplatin Chemical compound 0.000 claims description 2
- 229960005395 cetuximab Drugs 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
- 229960005420 etoposide Drugs 0.000 claims description 2
- 210000003608 fece Anatomy 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims description 2
- 229960005277 gemcitabine Drugs 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
- 229960004768 irinotecan Drugs 0.000 claims description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 2
- 229960004857 mitomycin Drugs 0.000 claims description 2
- 229950010203 nimotuzumab Drugs 0.000 claims description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 2
- 229960001756 oxaliplatin Drugs 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 229960001972 panitumumab Drugs 0.000 claims description 2
- 238000004632 predicting treatment efficacy Methods 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 230000004043 responsiveness Effects 0.000 claims description 2
- 238000011272 standard treatment Methods 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000000762 glandular Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2013/072638 | 2013-03-14 | ||
| PCT/CN2013/072638 WO2014139131A1 (en) | 2013-03-14 | 2013-03-14 | Use of egfr biomarkers for the treatment of gastric cancer with anti-egfr agents |
| PCT/US2014/028714 WO2014153018A1 (en) | 2013-03-14 | 2014-03-14 | Use of egfr biomarkers for the treatment of gastric cancer with anti-egfr agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019202804A Division JP2020040959A (ja) | 2013-03-14 | 2019-11-08 | 抗ｅｇｆｒ薬を用いた胃癌の処置のための、ｅｇｆｒバイオマーカーの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016515141A JP2016515141A (ja) | 2016-05-26 |
| JP2016515141A5 true JP2016515141A5 (cg-RX-API-DMAC7.html) | 2017-04-06 |
| JP6675300B2 JP6675300B2 (ja) | 2020-04-01 |
Family
ID=51535817
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502876A Expired - Fee Related JP6675300B2 (ja) | 2013-03-14 | 2014-03-14 | 抗ｅｇｆｒ薬を用いた胃癌の処置のための、ｅｇｆｒバイオマーカーの使用 |
| JP2019202804A Pending JP2020040959A (ja) | 2013-03-14 | 2019-11-08 | 抗ｅｇｆｒ薬を用いた胃癌の処置のための、ｅｇｆｒバイオマーカーの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019202804A Pending JP2020040959A (ja) | 2013-03-14 | 2019-11-08 | 抗ｅｇｆｒ薬を用いた胃癌の処置のための、ｅｇｆｒバイオマーカーの使用 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US10442862B2 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6675300B2 (cg-RX-API-DMAC7.html) |
| WO (2) | WO2014139131A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014139131A1 (en) | 2013-03-14 | 2014-09-18 | Crown Bioscience, Inc. | Use of egfr biomarkers for the treatment of gastric cancer with anti-egfr agents |
| US10484156B2 (en) * | 2016-11-16 | 2019-11-19 | Qualcomm Incorporated | Search space associated with physical downlink control channel based on channel quality indicators |
| US11459618B2 (en) | 2017-03-29 | 2022-10-04 | Crown Bioscience, Inc. (Taicang) | System and method for determining Cetuximab sensitivity on gastric cancer |
| WO2018226863A1 (en) * | 2017-06-06 | 2018-12-13 | University Of Maryland, College Park | Analysis of single cell mechanical phenotyping for metastatic detection |
| CN107582993A (zh) * | 2017-11-10 | 2018-01-16 | 兰志英 | 一种治疗胃癌的药物及其制备方法 |
| WO2020100969A1 (ja) * | 2018-11-14 | 2020-05-22 | 学校法人金沢医科大学 | びまん性胃がんを治療するための医薬組成物 |
| CN115197320A (zh) * | 2021-04-07 | 2022-10-18 | 中美冠科生物技术（太仓）有限公司 | 新型抗cd4抗体 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005117553A2 (en) | 2004-05-27 | 2005-12-15 | The Regents Of The University Of Colorado | Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients |
| CA2636074A1 (en) | 2006-01-04 | 2007-07-12 | University Of Montpellier 1 | Combination therapy using anti-egfr and anti-her2 antibodies |
| US8329421B2 (en) | 2007-07-13 | 2012-12-11 | Ventana Medical Systems, Inc. | Methods of predicting response of a neoplasm to an EGFR inhibitor and detecting interactions between EGFR and an EGFR regulatory protein |
| EP3216874A1 (en) * | 2008-09-05 | 2017-09-13 | TOMA Biosciences, Inc. | Methods for stratifying and annotating cancer drug treatment options |
| WO2012157647A1 (ja) | 2011-05-16 | 2012-11-22 | 大鵬薬品工業株式会社 | 胃癌患者に対するテガフール・ギメラシル・オテラシルカリウム配合剤及びｅｇｆｒ阻害剤からなる化学療法の選択方法 |
| WO2014139131A1 (en) | 2013-03-14 | 2014-09-18 | Crown Bioscience, Inc. | Use of egfr biomarkers for the treatment of gastric cancer with anti-egfr agents |
-
2013
- 2013-03-14 WO PCT/CN2013/072638 patent/WO2014139131A1/en not_active Ceased
-
2014
- 2014-03-14 JP JP2016502876A patent/JP6675300B2/ja not_active Expired - Fee Related
- 2014-03-14 WO PCT/US2014/028714 patent/WO2014153018A1/en not_active Ceased
- 2014-03-14 US US14/775,117 patent/US10442862B2/en active Active
-
2019
- 2019-11-08 JP JP2019202804A patent/JP2020040959A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Joshi et al. | Current treatment and recent progress in gastric cancer | |
| Ajani et al. | Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology | |
| De Jesus-Acosta et al. | Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma | |
| Bell et al. | Chemotherapy-induced COX-2 upregulation by cancer cells defines their inflammatory properties and limits the efficacy of chemoimmunotherapy combinations | |
| Ju et al. | A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma | |
| Pestana et al. | Histology-agnostic drug development—considering issues beyond the tissue | |
| Bollschweiler et al. | Current and future treatment options for esophageal cancer in the elderly | |
| Catenacci et al. | Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial | |
| Ilson et al. | A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus | |
| Carlson et al. | NCCN Task Force Report: adjuvant therapy for breast cancer | |
| Locati et al. | A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: translational analyses and clinical impact | |
| Iveson et al. | Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study | |
| Ajani et al. | Esophageal and esophagogastric junction cancers, version 1.2015 | |
| Fuchs et al. | Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab | |
| Stintzing et al. | Prognostic value of cetuximab‐related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: Results from a randomized trial of the GERMAN AIO CRC Study Group | |
| Ozols et al. | Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening—a report from the American Society of Clinical Oncology | |
| JP2016515141A5 (cg-RX-API-DMAC7.html) | ||
| Dakhel et al. | S100P antibody-mediated therapy as a new promising strategy for the treatment of pancreatic cancer | |
| Höller et al. | Diagnostic and prognostic biomarkers of luminal breast cancer: where are we now? | |
| Muller et al. | Expression of LRIG1 and LRIG3 correlates with human papillomavirus status and patient survival in cervical adenocarcinoma | |
| Wang et al. | CC motif chemokine ligand 5 (CCL5) levels in gastric cancer patient sera predict occult peritoneal metastasis and a poorer prognosis | |
| Jin et al. | Differential response to EGFR-and VEGF-targeted therapies in patient-derived tumor tissue xenograft models of colon carcinoma and related metastases | |
| Petrillo et al. | Biomarkers for precision treatment in gastric cancer | |
| Fleischmann et al. | ACO/ARO/AIO-21-Capecitabine-based chemoradiotherapy in combination with the IL-1 receptor antagonist anakinra for rectal cancer Patients: A phase I trial of the German rectal cancer study group | |
| Improta et al. | Coexistence of two different mutations in codon 12 of the Kras gene in colorectal cancer: Report of a case supporting the concept of tumoral heterogeneity |